Ireland - English - HPRA (Health Products Regulatory Authority)

dlrc pharma services limited - adrenaline - solution for injection - 0.1 milligram(s)/millilitre - adrenergic and dopaminergic agents; epinephrine

Ireland - English - HPRA (Health Products Regulatory Authority)

dlrc pharma services limited - adrenaline - solution for injection - 1 milligram(s)/millilitre - adrenergic and dopaminergic agents; epinephrine

Israel - English - Ministry of Health

a.l. medi-market ltd. - noradrenaline as tartrate - concentrate for solution for infusion - noradrenaline as tartrate 1 mg / 1 ml - norepinephrine - noradrenaline kalceks is indicated for blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). as an adjunct in the treatment of cardiac arrest and profound hypotension.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

base) 4mg/4ml concentrate for solution for infusion ampoules (aguettant ltd - noradrenaline acid tartrate - solution for infusion - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

base) 8mg/8ml concentrate for solution for infusion ampoules (aguettant ltd - noradrenaline acid tartrate - solution for infusion - 1mg/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - dobutamine hydrochloride 14 mg/ml equivalent to dobutamine 12.5 mg/ml, 250 mg dobutamine in 20 ml;   - concentrate for infusion - 12.5 mg/ml - active: dobutamine hydrochloride 14 mg/ml equivalent to dobutamine 12.5 mg/ml, 250 mg dobutamine in 20 ml   excipient: hydrochloric acid sodium metabisulfite water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. conditions which may precipitate such situations include the following hypoperfusion states: initially cardiac in origin: a. acute heart failure acute myocardial infarction, cardiogenic shock, following cardiac surgery, medicine-induced depression of cardiac contractility such as that which occurs in excessive ?-adrenergic receptor blockade. b. chronic heart failure acute decompensation of chronic congestive heart failure, temporary inotropic support in advanced chronic congestive heart failure, as an adjunct to therapy with conventional oral inotropic agents, systemic vasodilators, and diuretics. initially noncardiac in origin: acute hypoperfusion states secondary to trauma, surgery, sepsis, or hypovolaemia when mean arterial pressure is above 70-mm hg and pulmonary capillary wedge pressure is 18-mm hg or greater, with inadequate response to volume repletion and increased ventricular filling pressure, low cardiac output secondary to mechanical ventilation with positive end-expiratory pressure (peep). paediatric population: dobutamine is indicated in all paediatric age groups (from neonates to 18 years of age) as inotropic support in low cardiac output hypoperfusion states resulting from decompensated heart failure, following cardiac surgery, cardiomyopathies and in cardiogenic or septic shock. dobutamine stress echocardiography: dobutamine hydrochloride may be used as a substitute for physical exercise in stress testing in the diagnosis of coronary artery disease. precautions apply (refer to data sheet).

New Zealand - English - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - glucagon hydrochloride 1mg (recombinant);  ;   - solution for injection - 1 mg - active: glucagon hydrochloride 1mg (recombinant)     excipient: lactose monohydrate water for injection - therapeutic treatment of severe hypoglycaemic reactions, which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. to prevent the occurrence of secondary hypoglycaemia, oral carbohydrate should be given to restore the hepatic glycogen when the patient has responded to the treatment. the mechanism and hence treatment of sulfonylurea-induced hypoglycaemia differs from that of severe insulin-induced hypoglycaemia in some important ways. consciousness should preferably be restored by the administration of intravenous glucose. if glucagon is used due to the unavailability of intravenous glucose (e.g. before reaching a hospital) care should be taken to protect against secondary hypoglycaemia with constant monitoring of the patient's blood sugar level by medical personnel. subsequent administration of intravenous glucose may be required.

New Zealand - English - Medsafe (Medicines Safety Authority)

biomed limited - noradrenaline acid tartrate monohydrate 0.12 mg/ml equivalent to 0.06mg/ml noradrenaline base;   - solution for infusion - 0.06 mg/ml - active: noradrenaline acid tartrate monohydrate 0.12 mg/ml equivalent to 0.06mg/ml noradrenaline base   excipient: glucose sodium metabisulfite water for injection - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion, and drug reactions).

New Zealand - English - Medsafe (Medicines Safety Authority)

biomed limited - noradrenaline acid tartrate monohydrate 0.159 g/l equivalent to 0.08 g/l noradrenaline base - solution for infusion - 0.08 mg/ml - active: noradrenaline acid tartrate monohydrate 0.159 g/l equivalent to 0.08 g/l noradrenaline base excipient: glucose sodium metabisulfite water for injection - for the restoration of blood pressure in certain acute hypotensive states (e.g. phaeochromocytomectomy, sympathectomy, poliomyelitis, spinal anaesthesia, myocardial infarction, septicaemia, blood transfusion, and drug reactions).